New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity
Molecules · 2024
DOI: 10.3390/molecules29081758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Jiale Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical Univer…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Doxorubicin, Peptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province, the Scientific Research Projects of Hebei Province Education Department, Hebei Natural Science Foundation.
Abstract (Originalsprache)
Poor selectivity to tumor cells is a major drawback in the clinical application of the antitumor drug doxorubicin (DOX). Peptide–drug conjugates (PDCs) constructed by modifying antitumor drugs with peptide ligands that have high affinity to certain overexpressed receptors in tumor cells are increasingly assessed for their possibility of tumor-selective drug delivery. However, peptide ligands composed of natural L-configuration amino acids have the defects of easy enzymatic degradation and insufficient biological stability. In this study, two new PDCs (LT7-SS-DOX and DT7-SS-DOX) were designed and synthesized by conjugating a transferrin receptor (TfR) peptide ligand LT7 (HAIYPRH) and its retro-inverso analog DT7 (hrpyiah), respectively, with DOX via a disulfide bond linker. Both conjugates exhibited targeted antiproliferative effects on TfR overexpressed tumor cells and little toxicity to TfR low-expressed normal cells compared with free DOX. Moreover, the DT7-SS-DOX conjugate possessed higher serum stability, more sustained reduction-triggered drug release characteristics, and stronger in vitro antiproliferative activity as compared to LT7-SS-DOX. In conclusion, the coupling of antitumor drugs with the DT7 peptide ligand can be used as a promising strategy for the further development of stable and efficient PDCs with the potential to facilitate TfR-targeted drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hebei Province Key Laboratory of Research and Development of Traditional Chinese Medicine, Institute of Chinese Mateia Medica, Chengde Medical University, Chengde 067000, China.
- School of Basic Medical Sciences, Chengde Medical University, Chengde 067000, China.
ORCID-Profile: Songtao Li
Förderung
- Natural Science Foundation of Hebei Province
- the Scientific Research Projects of Hebei Province Education Department
- Hebei Natural Science Foundation
- Science Research Project of Hebei Education Department
Zitieren
APA
Yu, J., Mao, X., Yang, X., Zhao, G., & Li, S. (2024). New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity. Molecules. https://doi.org/10.3390/molecules29081758
Vancouver
Yu J, Mao X, Yang X, Zhao G, Li S. New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity. Molecules. 2024. doi:10.3390/molecules29081758
BibTeX
@article{Yu2024,
author = {Yu, Jiale and Mao, Xiaoxia and Yang, Xue and Zhao, Guiqin and Li, Songtao},
title = {New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29081758}
}
EUVIMED